Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) (GENTSMOKING)
Smoking Cessation, Genetic Predisposition
About this trial
This is an interventional treatment trial for Smoking Cessation focused on measuring varenicline, bupropion
Eligibility Criteria
Inclusion Criteria:
- smoking who wants to quit smoking, stable clinic diseases, depression or anxiety disorder stable for more than 3 months
Exclusion Criteria:
- contra indication for varenicline and or bupropion
- unstable psychiatric disorders.
- In the treatment of neoplastic diseases.
- Limitation to attend the medical visits
Sites / Locations
- Ambulatório de Tratamento Tabagismo - Incor HCFMUSP
Arms of the Study
Arm 1
Arm 2
No Intervention
Active Comparator
Group Varenicline
Group Genetic
Patients randomized to this group will collect polymorphisms at time zero and will receive varenicline for smoking cessation. The polymorphism result will only be known at the end of the protocol. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
The patients randomized to this arm will collect polymorphisms and could receive varenicline or bupropion or both depending on genetic polymorphisms for each one these drugs. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.